Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
Trial details
- Registry ID
- NCT06295731
- Drugs studied
- INBRX-106, Pembrolizumab
TrialRedline tracks 3 clinical trials sponsored by Inhibrx Biosciences, Inc: 1 Phase 2 / 3, 1 Phase 2, 1 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)NCT06295731 | INBRX-106, Pembrolizumab | Recruiting | 2029-12Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of INBRX-109 in Conventional ChondrosarcomaNCT04950075 | INBRX-109 | Active not recruiting | 2025-09-30Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)NCT04198766 | Carboplatin AUC-5, Carboplatin AUC-6, Cisplatin 75mg/m2, Gemcitabine (1000 mg/m2) and 6 more | Recruiting | 2033-07Estimated |
Names as written in the registry records.
NCT06295731 · Inhibrx Biosciences, Inc
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Phase 2: Objective Response Rate (ORR) Description: ORR is defined as the proportion of patients with a complete response (CR) or partial response (PR) on 2 consecutive occasions ≥4 weeks apart, per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Time frame: up to 6 months Measure: Phase 3: Progression-Free Survival (PFS) Description: PFS is defined as the time from randomization to first occurrence of PD, as determined by the Investigator according to RECIST v 1.1, or death from any cause (whichever occurs first). Time frame: From randomization to first occurrence of progressive disease (PD) or death (up to 4 years) Measure: Phase 3: Overall Survival (OS) Description: OS is the time from randomization to death due to any cause Time frame: From randomization until death from any cause (up to 4 years). After: Measure: Phase 2: Objective Response Rate by investigator (ORRinv) Description: defined as the proportion of patients with complete response (CR) or partial response (PR) on 2 consecutive occasions ≥4 weeks apart, as determined by the Investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Time frame: From randomization to progressive disease (PD) or death (up to 1 year) Measure: Phase 3: Progression-Free Survival by Investigator (PFSinv) Description: defined as the time from randomization to first occurrence of PD, as determined by the Investigator according to RECIST 1.1, or death from any cause (whichever occurs first). Time frame: From randomization to PD or death (up to 4 years) Measure: Phase 3: Overall Survival (OS) Description: defined as the time from randomization to death from any cause. Time frame: From randomization until death from any cause (up to 4 years).
Before: 410 participants (planned). After: 450 participants (planned).
Before: May 2029. After: Dec 2029.
Before: Active not recruiting. After: Recruiting.
NCT06295731 · Inhibrx Biosciences, Inc
Before: Recruiting. After: Active not recruiting.
NCT04950075 · Inhibrx Biosciences, Inc
Before: Estimated. After: Actual.
Before: 201 participants (planned). After: 206 participants (actual).
Before: Estimated. After: Actual.
Before: Sep 2025. After: 30 Sep 2025.
Before: Recruiting. After: Active not recruiting.